Development of Genome Editing Approaches against Herpes Simplex Virus Infections

被引:9
作者
Zhang, Isadora [1 ]
Hsiao, Zoe [1 ,2 ]
Liu, Fenyong [1 ,3 ]
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
[2] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA
[3] Univ Calif Berkeley, Program Comparat Biochem, Berkeley, CA 94720 USA
来源
VIRUSES-BASEL | 2021年 / 13卷 / 02期
关键词
herpesvirus; herpes simplex virus; genome editing; homing endonuclease; CRISPR; Cas9;
D O I
10.3390/v13020338
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Herpes simplex virus 1 (HSV-1) is a herpesvirus that may cause cold sores or keratitis in healthy or immunocompetent individuals, but can lead to severe and potentially life-threatening complications in immune-immature individuals, such as neonates or immune-compromised patients. Like all other herpesviruses, HSV-1 can engage in lytic infection as well as establish latent infection. Current anti-HSV-1 therapies effectively block viral replication and infection. However, they have little effect on viral latency and cannot completely eliminate viral infection. These issues, along with the emergence of drug-resistant viral strains, pose a need to develop new compounds and novel strategies for the treatment of HSV-1 infection. Genome editing methods represent a promising approach against viral infection by modifying or destroying the genetic material of human viruses. These editing methods include homing endonucleases (HE) and the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated protein (Cas) RNA-guided nuclease system. Recent studies have showed that both HE and CRISPR/Cas systems are effective in inhibiting HSV-1 infection in cultured cells in vitro and in mice in vivo. This review, which focuses on recently published progress, suggests that genome editing approaches could be used for eliminating HSV-1 latent and lytic infection and for treating HSV-1 associated diseases.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] New strategies against drug resistance to herpes simplex virus
    Yu-Chen Jiang
    Hui Feng
    Yu-Chun Lin
    Xiu-Rong Guo
    International Journal of Oral Science, 2016, 8 (01) : 1 - 6
  • [32] Combination of benzo[a]phenothiazines with acyclovir against herpes simplex virus
    Mucsi, I
    Molnár, J
    Motohashi, N
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) : 67 - 72
  • [33] Characterization of inhibitory action of concanamycins against herpes simplex virus
    Hayashi, K
    Kawauchi, M
    Nakai, C
    Sankawa, U
    Seto, H
    Hayashi, T
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 2001, 12 (01) : 51 - 59
  • [34] Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections
    Eo, SK
    Pack, C
    Kumaraguru, U
    Rouse, BT
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (02) : 213 - 225
  • [35] Herpes simplex virus infections among rural residents in eastern China
    Haijiang Lin
    Na He
    Meifang Su
    Jifu Feng
    Li Chen
    Meiyang Gao
    BMC Infectious Diseases, 11
  • [36] TOPICAL TREATMENT OF CUTANEOUS HERPES-SIMPLEX VIRUS-INFECTIONS
    SPRUANCE, SL
    FREEMAN, DJ
    ANTIVIRAL RESEARCH, 1990, 14 (06) : 305 - 321
  • [37] Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus
    Malik, Shiza
    Sah, Ranjit
    Ahsan, Omar
    Muhammad, Khalid
    Waheed, Yasir
    VACCINES, 2023, 11 (02)
  • [38] New strategies against drug resistance to herpes simplex virus
    Yu-Chen Jiang
    Hui Feng
    Yu-Chun Lin
    Xiu-Rong Guo
    International Journal of Oral Science, 2016, 8 : 1 - 6
  • [39] New strategies against drug resistance to herpes simplex virus
    Jiang, Yu-Chen
    Feng, Hui
    Lin, Yu-Chun
    Guo, Xiu-Rong
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2016, 8 (01) : 1 - 6
  • [40] The Intersection of Innate Immune Pathways with the Latent Herpes Simplex Virus Genome
    Cuddy, Sean R.
    Cliffe, Anna R.
    JOURNAL OF VIROLOGY, 2023, 97 (05)